Clinical Trial Detail

NCT ID NCT03390504
Title A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

transitional cell carcinoma

Therapies

Pembrolizumab

Erdafitinib

Docetaxel + Vinflunine

Age Groups: adult senior

No variant requirements are available.